NHE-9 Antibody (B-2): sc-515758

NHE-9 Antibody (B-2) is a mouse monoclonal IgG1 kappa light chain antibody that detects NHE-9 of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). NHE-9 Antibody (B-2) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. NHE-9, also known as SLC9A9 (solute carrier family 9 (sodium/hydrogen exchanger), member 9), is a 645 amino acid multi-pass membrane protein that is primarily localized to late endosomes and is a member of the monovalent cation/proton antiporter family of ion transporters. NHE-9 is expressed ubiquitously, with the highest levels found in heart and skeletal muscle, and lower levels in the liver, placenta, and kidney. NHE-9 plays a crucial role in the electroneutral exchange of sodium ions for protons across cellular membranes, which is vital for maintaining organelle ion homeostasis and overall cellular function. Disruptions in NHE-9 have been linked to early-onset behavioral and developmental disorders, including attention deficit-hyperactivity disorder and intellectual disability, highlighting its significance in neurodevelopmental processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

NHE-9 Antibody (B-2) References:

1. Disruption of a novel member of a sodium/hydrogen exchanger family and DOCK3 is associated with an attention deficit hyperactivity disorder-like phenotype.  |  de Silva, MG., et al. 2003. J Med Genet. 40: 733-40. PMID: 14569117
2. Four Na+/H+ exchanger isoforms are distributed to Golgi and post-Golgi compartments and are involved in organelle pH regulation.  |  Nakamura, N., et al. 2005. J Biol Chem. 280: 1561-72. PMID: 15522866
3. Synthesis and characterization of ruthenium and rhenium nucleosides.  |  Wang, P., et al. 2007. Inorg Chem. 46: 9853-62. PMID: 17948987
4. Genetics. Insights into the pathogenesis of autism.  |  Sutcliffe, JS. 2008. Science. 321: 208-9. PMID: 18621658
5. Identifying autism loci and genes by tracing recent shared ancestry.  |  Morrow, EM., et al. 2008. Science. 321: 218-23. PMID: 18621663
6. Genome-wide association scan of the time to onset of attention deficit hyperactivity disorder.  |  Lasky-Su, J., et al. 2008. Am J Med Genet B Neuropsychiatr Genet. 147B: 1355-8. PMID: 18937294
7. SLC9A9 mutations, gene expression, and protein-protein interactions in rat models of attention-deficit/hyperactivity disorder.  |  Zhang-James, Y., et al. 2011. Am J Med Genet B Neuropsychiatr Genet. 156B: 835-43. PMID: 21858920
8. Prognostic significance of SLC9A9 in patients with resectable esophageal squamous cell carcinoma.  |  Chen, J., et al. 2015. Tumour Biol. 36: 6797-803. PMID: 25835977
9. Autism spectrum disorder traits in Slc9a9 knock-out mice.  |  Yang, L., et al. 2016. Am J Med Genet B Neuropsychiatr Genet. 171B: 363-76. PMID: 26755066
10. SLC9A9 Co-expression modules in autism-associated brain regions.  |  Patak, J., et al. 2017. Autism Res. 10: 414-429. PMID: 27439572
11. Sodium hydrogen exchanger 9 NHE9 (SLC9A9) and its emerging roles in neuropsychiatric comorbidity.  |  Patak, J., et al. 2020. Am J Med Genet B Neuropsychiatr Genet. 183: 289-305. PMID: 32400953
12. Pomiferin targeting SLC9A9 based on histone acetylation modification pattern is a potential therapeutical option for gastric cancer with high malignancy.  |  Guang, D., et al. 2024. Biochem Pharmacol. 226: 116333. PMID: 38824966

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-NHE-9 Antibody (B-2) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-NHE-9 Antibody (B-2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

NHE-9 Antibody (B-2) Specifications

Alternate Product Name: NHE-9

Product Clone Name: B-2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 51-131

Epitope Target: NHE-9

Epitope Species: human

Product Reactivity/Detection: NHE-9

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for NHE-9 Antibody (B-2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin